Does MDR1 promoter methylation affect temozolomide resistance? A clinical study in patients with glioblastoma

Basit Öğe Kaydı
dc.authorscopusid57378188800
dc.authorscopusid55258248400
dc.authorscopusid57192910088
dc.authorscopusid12774456300
dc.authorscopusid55736672600
dc.authorscopusid57202749454
dc.authorscopusid56638467400
dc.contributor.authorGüner E.
dc.contributor.authorBayatlı E.
dc.contributor.authorKızıldoğan A.K.
dc.contributor.authorGökmen D.
dc.contributor.authorYüksek V.
dc.contributor.authorTaşpınar F.
dc.contributor.authorTetik B.
dc.date.accessioned2024-08-04T20:02:19Z
dc.date.available2024-08-04T20:02:19Z
dc.date.issued2022
dc.departmentİnönü Üniversitesien_US
dc.description.abstractPurpose: The multidrug resistance 1 (MDR1) gene expression and its epigenetic status may be an important factor in the chemotherapeutic resistance of glioblastoma (GB). The aim of this study was to analyze the effect of the MDR1 promoter methylation status on GB tumor tissue related to patient survival, chemotherapy resistance, and recurrence of the disease. Materials and methods: Thirty-six patients underwent surgery for GB at the Neurosurgery Department of Ankara University School of Medicine. The patients' clinical information and the MDR1 methylation status of the tumor tissues were compared to determine the effects on patient survival, chemotherapy resistance, and tumor recurrence. Results: Patients with MDR1 methylated GB had statistically significantly (p<0.001) shorter survival times. Early recurrence was detected in 25% of the patients with unmethylated tumor tissues and in 39.3% with hemimethylated tumor tissues. Conclusion: Instead of using the standard chemotherapeutics in all the patients with GB, tissue-specific medications must be chosen while taking into consideration the epigenomic characteristics and expression status of the tumor because of the genetic heterogeneity of GB. This is the first study to show the association between MDR1 promoter methylation and the clinical data of GB in the literature. © 2022, Pamukkale University. All rights reserved.en_US
dc.identifier.doi10.31362/patd.1013078
dc.identifier.endpage554en_US
dc.identifier.issn1309-9833
dc.identifier.issue3en_US
dc.identifier.scopus2-s2.0-85160747556en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage547en_US
dc.identifier.trdizinid1163616en_US
dc.identifier.urihttps://doi.org/10.31362/patd.1013078
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/1163616
dc.identifier.urihttps://hdl.handle.net/11616/91594
dc.identifier.volume15en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.language.isoenen_US
dc.publisherPamukkale Universityen_US
dc.relation.ispartofPamukkale Medical Journalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectChemotherapeutic resistanceen_US
dc.subjectglioblastomaen_US
dc.subjectmethylationen_US
dc.subjectmultidrug resistance 1en_US
dc.titleDoes MDR1 promoter methylation affect temozolomide resistance? A clinical study in patients with glioblastomaen_US
dc.title.alternativeMDR1 promoter metilasyonu temozolomid direncini etkiler mi? Glioblastomlu hastalarda klinik çalışmaen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu